Pharmacia Is “Recidivist” On GMPs, FDA Says After Two Warnings In 5 Years
Executive Summary
FDA considers two GMP warning letters issued to the same plant more than five years apart to be evidence that a company is "recidivist" on compliance issues, the agency told Pharmacia
You may also be interested in...
Risk-Based GMPs: FDA Priorities Will Reflect Exposure, Compliance Record
FDA's risk-based inspection model will consider a product's breadth of use when assigning inspection priorities
Pharmacia resolves warning letter issues
FDA is satisfied with Pharmacia's response to its April 17 warning letter relating to Caguas, Puerto Rico plant, company says (1"The Pink Sheet" May 20, p.7)...
Pharmacia resolves warning letter issues
FDA is satisfied with Pharmacia's response to its April 17 warning letter relating to Caguas, Puerto Rico plant, company says (1"The Pink Sheet" May 20, p.7)...